US Patent Issued to Amgen on July 7 for "RNAI constructs for inhibiting PNPLA3 expression and methods of use thereof" (California Inventors)

ALEXANDRIA, Va., July 7 -- United States Patent no. 12,674,166, issued on July 7, was assigned to Amgen Inc. (Thousand Oaks, Calif.).

"RNAI constructs for inhibiting PNPLA3 expression and methods of use thereof" was invented by Ingrid Rulifson (Palo Alto, Calif.), Justin K. Murray (Moorpark, Calif.), Michael Ollmann (San Carlos, Calif.) and Oliver Homann (Berkeley, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described."

The patent was filed on Dec. 10, 2019, under Application No. 17/31...